King of Prussia, PA – November 2024 – OCMS Bio is proud to announce that Dr. Ramdev Puligedda presented groundbreaking research at Antibody Engineering & Therapeutics 2024, highlighting the company’s innovative use of artificial intelligence (AI) in monoclonal antibody discovery.

Dr. Puligedda’s work focuses on leveraging AI-designed de novo antibody libraries to rapidly identify high-affinity binders for biologic targets. In collaboration with a partner company, OCMS Bio successfully screened a large AI-designed antibody library, demonstrating the power of its On-Cell mAb Screening (OCMS) platform to accelerate antibody discovery. The research provided critical insights into antibody ranking, function, and further refinement of AI-driven design methodologies.

“This presentation underscores OCMS Bio’s commitment to pushing the boundaries of antibody discovery,” said Dr. Scott Dessain, Chief Scientific Officer at OCMS Bio. “Dr. Puligedda’s work is a prime example of how AI and innovative screening technologies can redefine the speed and efficiency of developing therapeutic antibodies.”

OCMS Bio continues to lead the way in integrating AI-driven discovery with cutting-edge screening techniques, offering new opportunities for rapid therapeutic development.

For more information, visit ocms.bio.

Media Contact:
Thomas Halpern
COO
OCMS Bio
info@ocms.bio
678-626-7246